Chemotherapy (Antibiotics): General Principles of Antimicrobial Therapy

Introduction / Overview

Antimicrobial chemotherapy constitutes a cornerstone of modern medical practice, enabling the control and eradication of pathogenic microorganisms that threaten human health. The therapeutic relevance of antibiotics spans a wide spectrum, from routine treatment of common infections to the management of life‑threatening sepsis and the prevention of postoperative complications. The evolving landscape of antimicrobial resistance underscores the necessity for a deep understanding of drug mechanisms, pharmacokinetic and pharmacodynamic parameters, and the appropriate application of therapy in diverse patient populations.

Learning objectives for this chapter include:

• Elucidation of the fundamental principles guiding antimicrobial selection and dosing.
• Comprehensive description of antibiotic mechanisms of action and their pharmacodynamic correlates.
• Detailed appraisal of pharmacokinetic properties that influence therapeutic exposure.
• Recognition of major adverse effect profiles, safety considerations, and black‑box warnings.
• Identification of key drug‑drug interactions and contraindications that impact clinical decision‑making.

Classification

Drug Classes and Categories

Antibiotics are conventionally grouped according to structural similarity, mechanism of action, and spectrum of activity. The principal classes include:

• β‑Lactams (penicillins, cephalosporins, carbapenems, monobactams)
• Macrolides (erythromycin, azithromycin, clarithromycin)
• Lincosamides (clindamycin)
• Tetracyclines (doxycycline, minocycline)
• Aminoglycosides (gentamicin, amikacin, tobramycin)
• Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)
• Oxazolidinones (linezolid)
• Glycopeptides (vancomycin, teicoplanin)
• Polymyxins (colistin, polymyxin B)
• Others (sulfonamides, trimethoprim, rifamycins, nitroimidazoles, macrolide‑lincosamide‑streptogramin hybrids)

Each class exhibits distinct pharmacologic characteristics that influence both therapeutic efficacy and safety. For instance, β‑lactams act by inhibiting cell‑wall synthesis, whereas macrolides interfere with protein synthesis at the 50S ribosomal subunit.

Chemical Classification

From a chemical standpoint, antibiotics can be categorized into:

• Natural products derived from bacterial, fungal, or plant sources (e.g., penicillins, tetracyclines).
• Synthetic analogues engineered to enhance potency or reduce toxicity (e.g., cephalosporins, fluoroquinolones).
• Modified natural products with structural alterations designed to overcome resistance mechanisms (e.g., β‑lactamase‑stable penicillins).

Mechanism of Action

Pharmacodynamics

Antimicrobial agents are classified as bactericidal or bacteriostatic, reflecting their impact on bacterial proliferation. The primary pharmacodynamic endpoints include:

• Minimum inhibitory concentration (MIC) – the lowest drug concentration that prevents visible growth of a microorganism in vitro.
• Time above MIC (T_>MIC) – critical for β‑lactams and aminoglycosides.
• Peak concentration (C_max) – relevant for fluoroquinolones and vancomycin.
• AUC_0–24h/MIC ratio – the area under the concentration‑time curve over 24 hours relative to MIC, particularly important for fluoroquinolones and aminoglycosides.

For example, β‑lactam antibiotics inhibit transpeptidase enzymes essential for cross‑linking peptidoglycan strands, thereby inducing cell‑wall stress and lysis. Macrolides bind to the 50S ribosomal subunit, blocking translocation and inhibiting peptide elongation. Fluoroquinolones target DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Aminoglycosides disrupt the 30S ribosomal subunit, causing misreading of mRNA and production of faulty proteins that compromise cell integrity.

Receptor Interactions and Cellular Mechanisms

Receptor binding affinity and downstream signaling events have been extensively characterized in vitro. Bactericidal agents primarily cause irreversible damage, whereas bacteriostatic agents merely halt proliferation, allowing host immunity to eradicate the pathogen. The pharmacologic potency is often quantified by the static–bactericidal ratio (SCR), which predicts the likelihood of achieving a clinically meaningful response when the drug concentration equals the MIC.

Pharmacokinetics

Absorption

Oral antibiotics generally exhibit variable bioavailability due to factors such as pH sensitivity, intestinal permeability, and first‑pass metabolism. For instance, β‑lactams demonstrate high absorption rates (> 90%) when administered orally; however, amoxicillin may have reduced absorption in the presence of gastric acid modifiers. Intravenous formulations bypass absorption barriers, achieving 100% bioavailability and facilitating rapid therapeutic concentrations.

Distribution

Distribution is influenced by plasma protein binding, tissue permeability, and the presence of specialized compartments. Drugs with high lipophilicity, such as macrolides, accumulate in phagocytic cells and penetrate intracellular pathogens. Conversely, hydrophilic agents such as aminoglycosides have limited tissue penetration but achieve high plasma concentrations. The volume of distribution (V_d) can be expressed as:

C(t) = C₀ × e^-k_elt

where C(t) is the concentration at time t, C₀ is the initial concentration, and k_el is the elimination rate constant. The half‑life (t_1/2) is calculated as t_1/2 = 0.693 ÷ k_el.

Metabolism

Metabolic pathways vary among antibiotic classes. β‑Lactams are primarily hydrolyzed by plasma β‑lactamases and, to a lesser extent, hepatic amidases. Fluoroquinolones undergo glucuronidation and hydroxylation, whereas macrolides are metabolized via hepatic cytochrome P450 enzymes, particularly CYP3A4. The metabolic rate influences both drug exposure and the formation of active or inactive metabolites. Genetic polymorphisms affecting metabolic enzymes may alter drug clearance and efficacy.

Excretion

Renal clearance predominates for many antibiotics, with glomerular filtration, tubular secretion, and reabsorption shaping the elimination profile. Nephrotoxic agents such as aminoglycosides and vancomycin accumulate in renal tubular cells, necessitating dose adjustment in renal impairment. Hepatic excretion is relevant for agents with significant biliary elimination, such as azithromycin. The clearance (Cl) can be expressed as Cl = Dose ÷ AUC, where AUC is the area under the concentration‑time curve. The relationship between renal function and drug clearance is often linear, but saturation may occur at high concentrations.

Half‑Life and Dosing Considerations

Optimal dosing regimens are tailored to achieve desired pharmacodynamic targets while minimizing toxicity. For time‑dependent antibiotics, maintaining drug concentrations above MIC for ≥ 50–70% of the dosing interval is essential. For concentration‑dependent antibiotics, attaining a C_max / MIC ratio ≥ 8–10 or an AUC_0–24h / MIC ratio ≥ 40–70 is associated with superior outcomes. Dosing adjustments are guided by renal and hepatic function, age, weight, and the presence of comorbidities. Therapeutic drug monitoring (TDM) is recommended for agents with narrow therapeutic windows, such as vancomycin and aminoglycosides.

Therapeutic Uses / Clinical Applications

Approved Indications

Antibiotics are employed in a multitude of clinical scenarios, including:

• Community‑Acquired Pneumonia (CAP) – β‑lactams, macrolides, or fluoroquinolones depending on severity and risk factors.
• Severe Sepsis and Septic Shock – broad‑spectrum agents such as carbapenems or piperacillin‑tazobactam combined with an aminoglycoside.
• Skin and Soft Tissue Infections (SSTIs) – clindamycin or vancomycin for methicillin‑resistant Staphylococcus aureus (MRSA).
• Urinary Tract Infections (UTIs) – nitrofurantoin for uncomplicated cystitis; fluoroquinolones for complicated UTIs.
• Intra‑abdominal Infections – β‑lactam/β‑lactamase inhibitor combinations with metronidazole.
• HIV‑Associated Pneumocystis jirovecii Pneumonia (PJP) – trimethoprim‑sulfamethoxazole.

Off‑Label Uses

Off‑label indications are frequently employed based on clinical evidence and expert consensus. Examples include:

• Use of fluoroquinolones for atypical pneumonia in patients intolerant to macrolides.
• High‑dose penicillin G for neurosyphilis and meningococcal meningitis.
• Combination therapy with rifampin for prosthetic joint infections.
• Long‑term prophylaxis with macrolides for patients with cystic fibrosis to reduce exacerbations.

Adverse Effects

Common Side Effects

Adverse events vary by class but generally include gastrointestinal disturbances, dermatologic reactions, and alterations in laboratory parameters:

• β‑Lactams – rash, anaphylaxis, diarrhea, neutropenia.
• Macrolides – nausea, vomiting, QT prolongation.
• Aminoglycosides – ototoxicity, nephrotoxicity, neuromuscular blockade.
• Fluoroquinolones – tendinopathy, tendon rupture, central nervous system effects.
• Tetracyclines – photosensitivity, hepatotoxicity, pseudomembranous colitis.
• Vancomycin – red man syndrome, nephrotoxicity, auditory toxicity.

Serious / Rare Adverse Reactions

Serious adverse reactions require prompt recognition and management:

• Severe hypersensitivity reactions, including Stevens‑Johnson syndrome, especially with sulfonamides and carbamazepine.
• Clostridioides difficile colitis following broad‑spectrum antibiotic use.
• Nephrotoxicity associated with vancomycin and aminoglycosides, often dose‑dependent.
• Tendon rupture in fluoroquinolone users, particularly in patients over 60 years or receiving concomitant corticosteroids.

Black Box Warnings

Several antibiotic classes carry black‑box warnings that underscore the importance of risk‑benefit assessment:

• Fluoroquinolones – risk of tendon rupture, peripheral neuropathy, and CNS toxicity.
• Vancomycin – risk of nephrotoxicity and red‑man syndrome.
• Macrolides – risk of QT prolongation and torsades de pointes.

Drug Interactions

Major Drug‑Drug Interactions

Concomitant administration of antibiotics with other agents can alter pharmacokinetics or potentiate toxicity:

• Macrolides inhibit CYP3A4, increasing serum concentrations of statins, benzodiazepines, and oral contraceptives.
• Fluoroquinolones chelate divalent cations (e.g., calcium, magnesium), reducing absorption of oral iron preparations.
• Aminoglycosides may synergize with neuromuscular blocking agents, exacerbating weakness.
• β‑Lactams can precipitate with certain antiepileptics, reducing therapeutic levels.
• Co‑administration of vancomycin and non‑steroidal anti‑inflammatory drugs (NSAIDs) increases the risk of nephrotoxicity.

Contraindications

Certain antibiotics are contraindicated in specific patient populations or in the presence of particular comorbidities:

• Penicillins and cephalosporins are contraindicated in patients with a documented IgE‑mediated allergy.
• Fluoroquinolones are contraindicated in pregnant women due to potential cartilage damage in the fetus.
• Macrolides are contraindicated in patients with prolonged QT interval or existing arrhythmias.
• Aminoglycosides are contraindicated in patients with severe renal impairment unless dose adjustments are meticulously performed.

Special Considerations

Use in Pregnancy / Lactation

Antibiotic selection during pregnancy must balance maternal benefit against fetal risk. Penicillins, cephalosporins, and macrolides are generally considered safe. Fluoroquinolones and tetracyclines are avoided due to teratogenic potential. Excretion into breast milk varies; lactation is usually permitted with penicillins and certain macrolides, while aminoglycosides are discouraged due to risk of ototoxicity in infants.

Pediatric / Geriatric Considerations

Children require weight‑based dosing, and age‑dependent pharmacokinetics must be accounted for. For example, neonates have reduced hepatic clearance, necessitating lower doses of fluoroquinolones. In geriatric patients, decreased renal function and altered protein binding increase the risk of toxicity; thus, lower starting doses and careful monitoring are warranted.

Renal / Hepatic Impairment

Renal impairment necessitates dose reductions or extended dosing intervals for renally cleared agents such as aminoglycosides, vancomycin, and fluoroquinolones. Hepatic impairment affects drugs metabolized by the liver, such as macrolides and fluoroquinolones. Monitoring of serum drug levels and adjustment of dosing regimens are essential to avoid accumulation and adverse events.

Summary / Key Points

• Antibiotic therapy is guided by pharmacodynamic targets (T_>MIC, C_max, AUC_0–24h / MIC).
• Time‑dependent agents require sustained concentrations above MIC, whereas concentration‑dependent agents rely on peak exposure.
• Pharmacokinetic properties—including absorption, distribution, metabolism, and excretion—dictate the optimal dosing strategy.
• Adverse effect profiles vary by class; black‑box warnings highlight critical safety concerns.
• Drug interactions, particularly involving CYP450 enzymes and renal excretion, must be considered to prevent toxicity.
• Special populations (pregnant, lactating, pediatric, geriatric, renal/hepatic impairment) demand individualized dosing and vigilant monitoring.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.